Table 2.
Cardiovascular drugs used during the follow-up period*
| Drug class, n (%) | Deterioration in glucose tolerance (n = 24) | No deterioration in glucose tolerance (n = 56) | P value |
|---|---|---|---|
| Diuretics |
6 (25%) |
15 (27%) |
0.87 |
| β-blockers |
19 (79%) |
50 (89%) |
0.23 |
| α1-blockers |
5 (21%) |
11 (20%) |
0.91 |
| Calcium channel blockers |
10 (42%) |
19 (34%) |
0.51 |
| Angiotensin receptor antagonists |
2 (8%) |
3 (5%) |
0.61 |
| Long-acting nitrates | 9 (38%) | 20 (36%) | 0.88 |
* Besides low-dose aspirin, angiotensin-converting enzyme inhibitors, statins and clopidogrel.